Everest On Licensing Spree After Investors Raise Stakes
Following recent investor signals of confidence, Everest signs flurry of new deals to build its innovative portfolio in APAC.
Scrip - June 9, 2026

FDA Breakthrough Device Data Shows Surge In Diagnostic Designations
Updated breakthrough device program data released by the US FDA on June 5 show a jump in the number of diagnostics accepted to the program, the level of new designations holding steady, and the persistence of the so-called “valley of death” that separates designation from marketing authorization.
Medtech Insight - June 8, 2026

G8 Is Not The Next G7, Says Dexcom CEO Jake Leach. Here Is What It Actually Is
CEO Jake Leach maps out the path from diabetes device maker to full-spectrum metabolic health platform — with new silicon, hospital ambitions, and a dietitian coaching business now in the fold.
Medtech Insight - June 8, 2026

Deals Shaping The Medtech And Diagnostics Industries, May 2026
An interactive look at medtech and diagnostics deals made during May 2026. Data courtesy of Biomedtracker.
Medtech Insight - June 8, 2026

Dexcom G7 Adds Five Hours Of Daily Time In Range Over Standard Care, Trial Shows
A 26-week randomized trial in non-insulin type 2 patients has handed Dexcom its most consequential clinical result yet — Level A evidence that continuous glucose monitoring meaningfully outperforms standard care in a population that guidelines have largely left behind.
Medtech Insight - June 8, 2026

Industry Urges Dedicated Support For Europe’s €13B IVD Sector
Position paper on IVDR revision welcomes many of the EU’s proposed changes, but requests tweaks to orphan diagnostics, risk classifications and health institution tests.
Medtech Insight - June 8, 2026

US Supplement Industry Faces One Tariff Hike With Another Looming From Trade Investigations
Proposed tariffs connected to USTR finding of forced labor, which will be subject of hearings on July 7, are additional 10% on imports from Canada, Mexico, Taiwan, Pakistan, the UK and EU nations and 12.5% for 45 others including China, India and Japan.
HBW Insight - June 8, 2026

US FDA Finds Sky-High Mercury Levels In Seven Skin-Lighteners
The US Food and Drug Administration found mercury in seven skin care products on the market at levels thousands of times higher than the trace amounts permitted; most products were sold on eBay.
HBW Insight - June 8, 2026

People On The Move: Appointments At Bayer Consumer Health, ANEFP, IADSA
A round-up of the latest people news: Bayer Consumer Health makes leadership appointments; ANEFP names president; IADSA elects chair; PGEU appoints 2027 president.
HBW Insight - June 8, 2026

OTC Industry Warned: Don’t Lose Sight Of Community Pharmacy
AESGP Annual Meeting: Community pharmacy risks being overlooked as manufacturers chase online growth, despite evidence it remains the industry's most powerful conversion channel and an untapped source of long-term revenue.
HBW Insight - June 8, 2026

Krka Aspires For Top Five Generics Position In All Traditional Markets
As the Slovenian pharma giant continues to scale its products with an evidently strong revenue growth, it hopes to prove that consistency equals European market success.
Generics Bulletin - June 8, 2026

India Gains Biologics Muscle As Aurobindo Opens TheraNym
Aurobindo’s TheraNym launch gives India a rare integrated biologics CMO platform, anchored by MSD, with 120,000 liters of planned capacity and ambitions to compete in global supply chains by 2030.
Generics Bulletin - June 8, 2026

Alvotech Refiles Golimumab and Aflibercept In US
Alvotech has now resubmitted filings to the US FDA for its biosimilar rivals to Simponi/Simponi Aria (golimumab) and Eylea (aflibercept), after working to resolve compliance issues relating to its Reykjavik manufacturing facility.
Generics Bulletin - June 8, 2026

AstraZeneca’s No-Equity Incubator: How BioVentureHub Selects For Synergy, Not Ownership
When public co-funding dried up in 2024, AstraZeneca did not wind down its Gothenburg incubator. It chose to run the Hub independently. The model that emerged is a no-equity, access-for-synergies platform: 26 groups working on tech AstraZeneca needs, housed inside inside its R&D campus.
In Vivo - June 8, 2026

Podcast: GATC Health’s Derisq AI, A FICO Score For Drug Development
In this episode of the In Vivo podcast, GATC Health's Tyrone Lam discusses Derisq AI, the techbio's simulation platform, as a neutral “Switzerland” for drugs, de?risking trials, insurance underwriting and pharma–biotech deal decisions.
In Vivo - June 8, 2026